Fig. 5From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectivesSome key issues requiring further mechanistic exploration. Comprehensive studies based on these issues will help researchers develop new biomarkers to prevent, monitor and manage irAEs during ICI therapy in patients with TETs. Autoimmune T cells and a disturbed TCR repertoire seem most relevant to irAEs, and a preclinical mouse model of irAEs is urgently needed to provide an ideal platform for mechanistic studies of irAEs. irAEs: Immune-related adverse events; ICIs: Immune checkpoint inhibitors; TETs: Thymic epithelial tumorsBack to article page